Cerebrospinal fluid biomarkers in Parkinson disease

Lucilla Parnetti, Anna Castrioto, Davide Chiasserini, Emanuele Persichetti, Nicola Tambasco, Omar Ali El-Agnaf, Paolo Calabresi

Research output: Contribution to journalReview article

109 Citations (Scopus)

Abstract

Clinical diagnosis of Parkinson disease (PD) is difficult in early stages of disease, with high risk of misdiagnosis. The long preclinical phase of PD provides the possibility for early therapeutic intervention once disease-modifying therapies have been developed, but lack of biomarkers for early diagnosis and monitoring of disease progression represents a major obstacle to achievement of this goal. Accordingly, research efforts aimed at identification of novel biomarkers have been increasing in the past 5 years. Cerebrospinal fluid (CSF) is an accessible source of brain-derived proteins, which mirror molecular changes that take place in the CNS. In this Review, we discuss evidence from numerous studies that have focused on identification of candidate CSF biomarkers for PD. Notably, molecular pathways related to α-synuclein, tau and β-amyloid peptides have received considerable attention. CSF levels of the protein DJ-1 are also of interest, although further investigation of this candidate marker is required. These studies support the usefulness of a combination of various CSF biomarkers of PD to increase diagnostic accuracy during early phases of the disease, and to differentiate PD from other neurodegenerative disorders.

Original languageEnglish
Pages (from-to)131-140
Number of pages10
JournalNature Reviews Neurology
Volume9
Issue number3
DOIs
Publication statusPublished - Mar 2013
Externally publishedYes

Fingerprint

Parkinson Disease
Cerebrospinal Fluid
Biomarkers
Synucleins
Cerebrospinal Fluid Proteins
Diagnostic Errors
Amyloid
Neurodegenerative Diseases
Disease Progression
Early Diagnosis
Peptides
Brain
Therapeutics
Research
Proteins

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., Ali El-Agnaf, O., & Calabresi, P. (2013). Cerebrospinal fluid biomarkers in Parkinson disease. Nature Reviews Neurology, 9(3), 131-140. https://doi.org/10.1038/nrneurol.2013.10

Cerebrospinal fluid biomarkers in Parkinson disease. / Parnetti, Lucilla; Castrioto, Anna; Chiasserini, Davide; Persichetti, Emanuele; Tambasco, Nicola; Ali El-Agnaf, Omar; Calabresi, Paolo.

In: Nature Reviews Neurology, Vol. 9, No. 3, 03.2013, p. 131-140.

Research output: Contribution to journalReview article

Parnetti, L, Castrioto, A, Chiasserini, D, Persichetti, E, Tambasco, N, Ali El-Agnaf, O & Calabresi, P 2013, 'Cerebrospinal fluid biomarkers in Parkinson disease', Nature Reviews Neurology, vol. 9, no. 3, pp. 131-140. https://doi.org/10.1038/nrneurol.2013.10
Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, Ali El-Agnaf O et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nature Reviews Neurology. 2013 Mar;9(3):131-140. https://doi.org/10.1038/nrneurol.2013.10
Parnetti, Lucilla ; Castrioto, Anna ; Chiasserini, Davide ; Persichetti, Emanuele ; Tambasco, Nicola ; Ali El-Agnaf, Omar ; Calabresi, Paolo. / Cerebrospinal fluid biomarkers in Parkinson disease. In: Nature Reviews Neurology. 2013 ; Vol. 9, No. 3. pp. 131-140.
@article{8934ef3d9c3747c0b3e657e496b75ba5,
title = "Cerebrospinal fluid biomarkers in Parkinson disease",
abstract = "Clinical diagnosis of Parkinson disease (PD) is difficult in early stages of disease, with high risk of misdiagnosis. The long preclinical phase of PD provides the possibility for early therapeutic intervention once disease-modifying therapies have been developed, but lack of biomarkers for early diagnosis and monitoring of disease progression represents a major obstacle to achievement of this goal. Accordingly, research efforts aimed at identification of novel biomarkers have been increasing in the past 5 years. Cerebrospinal fluid (CSF) is an accessible source of brain-derived proteins, which mirror molecular changes that take place in the CNS. In this Review, we discuss evidence from numerous studies that have focused on identification of candidate CSF biomarkers for PD. Notably, molecular pathways related to α-synuclein, tau and β-amyloid peptides have received considerable attention. CSF levels of the protein DJ-1 are also of interest, although further investigation of this candidate marker is required. These studies support the usefulness of a combination of various CSF biomarkers of PD to increase diagnostic accuracy during early phases of the disease, and to differentiate PD from other neurodegenerative disorders.",
author = "Lucilla Parnetti and Anna Castrioto and Davide Chiasserini and Emanuele Persichetti and Nicola Tambasco and {Ali El-Agnaf}, Omar and Paolo Calabresi",
year = "2013",
month = "3",
doi = "10.1038/nrneurol.2013.10",
language = "English",
volume = "9",
pages = "131--140",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Cerebrospinal fluid biomarkers in Parkinson disease

AU - Parnetti, Lucilla

AU - Castrioto, Anna

AU - Chiasserini, Davide

AU - Persichetti, Emanuele

AU - Tambasco, Nicola

AU - Ali El-Agnaf, Omar

AU - Calabresi, Paolo

PY - 2013/3

Y1 - 2013/3

N2 - Clinical diagnosis of Parkinson disease (PD) is difficult in early stages of disease, with high risk of misdiagnosis. The long preclinical phase of PD provides the possibility for early therapeutic intervention once disease-modifying therapies have been developed, but lack of biomarkers for early diagnosis and monitoring of disease progression represents a major obstacle to achievement of this goal. Accordingly, research efforts aimed at identification of novel biomarkers have been increasing in the past 5 years. Cerebrospinal fluid (CSF) is an accessible source of brain-derived proteins, which mirror molecular changes that take place in the CNS. In this Review, we discuss evidence from numerous studies that have focused on identification of candidate CSF biomarkers for PD. Notably, molecular pathways related to α-synuclein, tau and β-amyloid peptides have received considerable attention. CSF levels of the protein DJ-1 are also of interest, although further investigation of this candidate marker is required. These studies support the usefulness of a combination of various CSF biomarkers of PD to increase diagnostic accuracy during early phases of the disease, and to differentiate PD from other neurodegenerative disorders.

AB - Clinical diagnosis of Parkinson disease (PD) is difficult in early stages of disease, with high risk of misdiagnosis. The long preclinical phase of PD provides the possibility for early therapeutic intervention once disease-modifying therapies have been developed, but lack of biomarkers for early diagnosis and monitoring of disease progression represents a major obstacle to achievement of this goal. Accordingly, research efforts aimed at identification of novel biomarkers have been increasing in the past 5 years. Cerebrospinal fluid (CSF) is an accessible source of brain-derived proteins, which mirror molecular changes that take place in the CNS. In this Review, we discuss evidence from numerous studies that have focused on identification of candidate CSF biomarkers for PD. Notably, molecular pathways related to α-synuclein, tau and β-amyloid peptides have received considerable attention. CSF levels of the protein DJ-1 are also of interest, although further investigation of this candidate marker is required. These studies support the usefulness of a combination of various CSF biomarkers of PD to increase diagnostic accuracy during early phases of the disease, and to differentiate PD from other neurodegenerative disorders.

UR - http://www.scopus.com/inward/record.url?scp=84874948898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874948898&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2013.10

DO - 10.1038/nrneurol.2013.10

M3 - Review article

VL - 9

SP - 131

EP - 140

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 3

ER -